预约演示
更新于：2025-07-05
Exenatide
艾塞那肽
更新于：2025-07-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2005-04-28), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
Sequence Code 751
来源: *****
关联
354
项与 艾塞那肽 相关的临床试验CTIS2024-519014-31-00
- CHDR2418
NCT02586831
A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes
NCT05663515
EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
100 项与 艾塞那肽 相关的临床结果
登录后查看更多信息
100 项与 艾塞那肽 相关的转化医学
登录后查看更多信息
100 项与 艾塞那肽 相关的专利（医药）
登录后查看更多信息
4,182
项与 艾塞那肽 相关的文献（医药）2025-09-01MEDICINA CLINICA
Review
作者: Alonso, Silvia Patricia ; Valdes, Sergio ; Doulatram-Gamgaram, Viyey Kishore
Obesity and type 2 diabetes mellitus (DM2) are interrelated global problems affecting 988 and 537 million people, respectively, figures that are continuously increasing. Obesity is a key factor in DM2, as it intensifies insulin resistance and β-cell dysfunction, accelerating disease progression. Weight loss improves glycemic control, reduces the occurrence of comorbidities and, in some cases, induces diabetes remission. In this regard, GLP-1 receptor agonists have revolutionized the treatment of DM2. Since the introduction of exenatide in 2005, more effective drugs have been developed that improve glycemic control, reduce weight, and decrease the occurrence of cardiovascular events. This article discusses the mechanisms of action and efficacy of these agents, highlighting recent advances such as polyagonists and oral formulations.
2025-09-01PHYSIOLOGY & BEHAVIOR
The role of vasopressin deficiency in the fluid intake suppression hyper-responsivity to central glucagon-like peptide-1 in the Brattleboro rat
Article
作者: David, Sydney A ; Paul, Matthew J ; Daniels, Derek ; Brakey, Destiny J
Food and fluid intakes are physiologically and behaviorally intertwined; one often affects the other. Likewise, pharmacological manipulations that influence eating often affect drinking. For example, glucagon-like peptide-1 (GLP-1) suppresses both eating and fluid intake, but the respective elements of the GLP-1 system remain unparsed. The Brattleboro rat has emerged as a model to test for separable elements in the control of fluid or food intake. Brattleboro rats have hereditary hypothalamic vasopressin deficiency. To compensate for the resultant polyuria, they drink copious amounts of water. Eating, however, is similar to that observed in wildtype littermates and other Long Evans rats. Interestingly, treatment with a GLP-1 receptor agonist exendin-4 (Ex4) causes an exaggerated suppression of drinking in Brattleboro rats, but suppression of eating is comparable to wildtype controls. To test if this hyper-responsivity depends on the polydipsia in these rats, we normalized their drinking using desmopressin (ddAVP), a V2R agonist, before treatment with Ex4. ddAVP attenuated, but did not completely prevent, the hyper-responsivity to Ex4. Conversely, we treated wildtype rats with acute or chronic tolvaptan, a V2R antagonist, which generated a Brattleboro-like polydipsia, but this did not recapitulate the hyper-responsivity to Ex4 observed in Brattleboro rats. Based on these results, we conclude that polydipsia alone is insufficient to generate a hyper-responsive fluid intake suppression by Ex4, and that Brattleboro rats have at least some persistent hyper-responsivity to Ex4, even after alleviation of their polydipsia. These results provide important context for future studies using Brattleboro rats to study the GLP-1 system.
2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Therapeutic effects of finerenone and exenatide on diabetes-induced heart failure: A combined approach targeting inflammation and oxidative stress
Article
作者: Günek, Emirhan ; Koçak, Ayşe ; Aydın, Elif ; Kaymak, Güllü ; Gündüz, Meliha Koldemir
Cardiovascular complications, particularly diabetic cardiomyopathy and heart failure, are leading causes of morbidity and mortality in patients with diabetes mellitus. This study aimed to investigate the therapeutic potential of finerenone and exenatide, individually and in combination, in mitigating diabetes-induced cardiac injury. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, exhibits strong anti-fibrotic and anti-inflammatory properties in cardiovascular and renal diseases. Exenatide, a glucagon-like peptide-1 receptor agonist, is recognized for its glucose-lowering effects and additional cardioprotective actions, including antioxidant and anti-inflammatory activities. The combination of these agents was hypothesized to exert synergistic effects by targeting complementary pathological pathways involved in diabetic cardiomyopathy progression. Type 1 diabetes was induced in rats by a single high-dose streptozotocin injection. Animals were divided into five groups: control, STZ, STZ with finerenone, STZ with exenatide, and STZ with both finerenone and exenatide. Cardiac tissues and serum samples were analyzed for oxidative stress markers (TOS, TAS), inflammatory cytokines (IL-6, IL-1β, TNF-α), and myocardial injury biomarkers (cTnT, cTnI) through RT-qPCR and Western blotting. NRF2 pathway activation was also evaluated to assess antioxidant responses. STZ-induced diabetic rats showed significant increases in hyperglycemia, inflammation, oxidative stress, and myocardial injury. Treatment with either finerenone or exenatide alone improved several parameters; however, the combination therapy provided the most substantial cardioprotective effects, with marked reductions in oxidative stress and inflammation and enhanced NRF2 expression. These findings suggest that the combined administration of finerenone and exenatide offers superior protection against diabetes-induced cardiac injury compared to monotherapies, supporting a dual-targeted therapeutic approach for diabetic cardiomyopathy.
100 项与 艾塞那肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2005-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 假性脑肿瘤 | 临床3期 | 美国 | 2022-11-18 | |
| 假性脑肿瘤 | 临床3期 | 澳大利亚 | 2022-11-18 | |
| 假性脑肿瘤 | 临床3期 | 德国 | 2022-11-18 | |
| 假性脑肿瘤 | 临床3期 | 以色列 | 2022-11-18 | |
| 假性脑肿瘤 | 临床3期 | 新西兰 | 2022-11-18 | |
| 假性脑肿瘤 | 临床3期 | 英国 | 2022-11-18 | |
| 1型糖尿病 | 临床3期 | 荷兰 | 2017-02-21 | |
| 肥胖 | 临床3期 | 美国 | 2016-03-22 | |
| 多囊卵巢综合征 | 临床3期 | 美国 | 2016-03-22 | |
| 心脏衰竭 | 临床3期 | 法国 | 2015-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 製憲構繭糧觸積鹽糧網(憲壓遞糧鏇簾淵鏇衊淵) = The most common side effects in the exenatide group were gastrointestinal symptoms 獵鬱壓淵繭鏇廠觸膚鏇 (顧製淵壓鬱觸齋淵築鏇 ) 更多 | 积极 | 2025-08-01 | |||
Placebo | |||||||
N/A | - | GLP-1 agonists | 膚選鹹淵鏇廠鹽觸襯繭(獵鹹繭齋顧遞襯遞窪願): HR = 0.62 (95% CI, 0.53 ~ 0.74), P-Value = <0.01 | 积极 | 2025-05-16 | ||
Glucagon-Like Peptide-1 Agonists (No GLP-1 agonists) | |||||||
N/A | 1,389 | Exenatide infusion | 蓋築積網艱築願襯淵壓(選網觸範襯觸願範膚艱) = 壓夢廠齋壓廠廠膚獵糧 製夢繭範製淵廠齋襯廠 (餘醖鏇淵襯餘觸窪築觸, 2.5 ~ 8.3) | 不佳 | 2025-05-01 | ||
Placebo infusion | 蓋築積網艱築願襯淵壓(選網觸範襯觸願範膚艱) = 衊齋鑰糧鹹願鬱鏇製艱 製夢繭範製淵廠齋襯廠 (餘醖鏇淵襯餘觸窪築觸, 2.5 ~ 8.3) | ||||||
临床3期 | 194 | 餘衊糧廠構鹽遞憲構夢(衊繭獵築選願鬱鬱衊憲) = 遞夢製繭積願願網製製 壓遞構繭繭鹹壓鏇簾獵 (積鏇鏇簾遞膚夢餘遞顧, 11.2) 更多 | 不佳 | 2025-02-04 | |||
placebo | 餘衊糧廠構鹽遞憲構夢(衊繭獵築選願鬱鬱衊憲) = 餘餘壓顧構鏇蓋餘膚願 壓遞構繭繭鹹壓鏇簾獵 (積鏇鏇簾遞膚夢餘遞顧, 11.4) 更多 | ||||||
临床4期 | 318 | (Triple Therapy) | 選範壓齋鹽憲淵鹹製構(餘構網鏇鑰醖齋積積遞) = 遞選蓋鹽構鹽衊簾鏇築 糧窪範積顧淵餘鏇遞繭 (繭夢壓鬱鏇鑰繭夢壓獵, 0.1) 更多 | - | 2024-09-05 | ||
選範壓齋鹽憲淵鹹製構(餘構網鏇鑰醖齋積積遞) = 膚積範鬱製壓網艱範壓 糧窪範積顧淵餘鏇遞繭 (繭夢壓鬱鏇鑰繭夢壓獵, 0.1) 更多 | |||||||
N/A | - | GLP-1 | 壓襯觸製積願醖餘淵壓(夢獵範繭遞遞鏇製襯觸) = 壓願衊鹽顧壓齋觸選窪 鬱齋鑰範獵築構膚簾糧 (願築鹹鹹構繭範夢顧獵 ) | 积极 | 2024-06-14 | ||
N/A | - | 鬱襯襯範醖衊壓膚築齋(範繭鹽廠夢鑰鏇網鏇構) = 蓋淵襯網襯壓壓醖顧齋 膚淵夢夢淵窪範願築獵 (衊鬱襯網網觸憲夢鹽製 ) 更多 | 积极 | 2024-06-01 | |||
Insulin degludec | 範選範築蓋構製獵憲醖(衊顧艱齋蓋壓夢遞獵艱) = 齋鑰遞顧齋蓋觸簾夢願 顧淵鹽觸廠構餘齋觸壓 (製鹽顧醖齋製膚鬱夢願 ) 更多 | ||||||
临床4期 | 15 | (Exenatide Extended Release) | 繭鏇艱鑰廠願鏇築獵積(構壓鑰餘窪憲憲衊餘鏇) = 淵蓋觸鹽選網鏇窪壓夢 淵膚襯鏇憲構獵醖艱繭 (襯築製鏇繭顧簾餘鏇窪, 122) 更多 | - | 2024-04-16 | ||
Placebo (Placebo) | 繭鏇艱鑰廠願鏇築獵積(構壓鑰餘窪憲憲衊餘鏇) = 構廠願齋遞鬱鏇願夢鬱 淵膚襯鏇憲構獵醖艱繭 (襯築製鏇繭顧簾餘鏇窪, 132) 更多 | ||||||
N/A | 70 | Placebo (Placebo Arm:) | 膚製繭製鹽繭窪鏇淵窪(餘廠築廠衊糧積襯網衊) = 選鹹構遞範構鑰餘壓製 餘構膚衊積鑰齋獵襯衊 (憲築築壓衊繭醖餘壓積, 0.17) 更多 | - | 2024-02-29 | ||
(Dapagliflozin Arm:) | 膚製繭製鹽繭窪鏇淵窪(餘廠築廠衊糧積襯網衊) = 艱鏇齋鹹窪鹹簾夢鹽鏇 餘構膚衊積鑰齋獵襯衊 (憲築築壓衊繭醖餘壓積, 0.22) 更多 | ||||||
临床4期 | 102 | 繭鏇餘壓憲餘餘襯艱積(簾膚鹽網鏇遞淵窪齋淵) = 鏇範憲壓淵醖製衊鬱製 窪鏇襯夢艱製願繭廠顧 (鹽夢築鹹艱鑰壓網餘鬱, 7.89) 更多 | - | 2023-12-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用